Regulatory implications of ctDNA in immuno-oncology for solid tumors

In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a minimally invasive approach for the diagnosis and management of patients with cancer and as an enrichment tool in clinical trials. In recent years, the US Food and Drug Administration has approved multiple ctDNA-...

Descripción completa

Detalles Bibliográficos
Autores principales: Vellanki, Paz J, Ghosh, Soma, Pathak, Anand, Fusco, Michael J, Bloomquist, Erik W, Tang, Shenghui, Singh, Harpreet, Philip, Reena, Pazdur, Richard, Beaver, Julia A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936292/
https://www.ncbi.nlm.nih.gov/pubmed/36796877
http://dx.doi.org/10.1136/jitc-2022-005344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936292/
https://www.ncbi.nlm.nih.gov/pubmed/36796877
http://dx.doi.org/10.1136/jitc-2022-005344

Ejemplares similares